CN Patent

CN109379891A — 作为激肽释放酶抑制剂的n-[(3-氟-4-甲氧基吡啶-2-基)甲基]-3-(甲氧基甲基)-1-({4-[(2-氧代吡啶-1-基)甲基]苯基}甲基)吡唑-4-甲酰胺的多晶型

Assigned to Kalvista Pharmaceuticals Ltd · Expires 2019-02-22 · 7y expired

What this patent protects

本发明提供了N‑[(3‑氟‑4‑甲氧基吡啶‑2‑基)甲基]‑3‑(甲氧基甲基)‑1‑({4‑[(2‑氧代吡啶‑1‑基)甲基]苯基}甲基)吡唑‑4‑甲酰胺及其盐的新型多晶型、含有其的药物组合物以及其在治疗中作为激肽释放酶抑制剂的用途。

USPTO Abstract

本发明提供了N‑[(3‑氟‑4‑甲氧基吡啶‑2‑基)甲基]‑3‑(甲氧基甲基)‑1‑({4‑[(2‑氧代吡啶‑1‑基)甲基]苯基}甲基)吡唑‑4‑甲酰胺及其盐的新型多晶型、含有其的药物组合物以及其在治疗中作为激肽释放酶抑制剂的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN109379891A
Jurisdiction
CN
Classification
—
Expires
2019-02-22
Drug substance claim
No
Drug product claim
No
Assignee
Kalvista Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.